Replies to post #23662 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

Opportunity, you are confused about who actually determines the direction of medicine and medical testing.

It is not Moro or the research scientists at the ISOBM. Those scientists work to develop tools but ultimately, the thought leaders determine which if any of those tools are useful.

Here is a list of thought leaders in each field.

**************************************************
SAN FRANCISCOSan Francisco

Thought Leader Reports(TM). The company surveyed a national sample of hematologist/oncologists and medical oncologists medical oncologist Oncology An oncologist who diagnoses and treats cancer with chemotherapy, hormones, biologicals, or immunologic agents; the MO becomes a cancer Pt's de facto primary care giver, and coordinates treatment provided by other specialists. . Based on approximately 600 survey responses, national and local thought leaders, also known as key opinion leaders, were ranked for each tumor tumor: see neoplasm. type. The highest ranked national thought leaders are shown below:
Cancer Type Top 3 Thought Leaders Ranked by
Hematologist/Oncologists
-------------- -----------------------------------------------------
Breast Larry Norton, MD (Memorial Sloan-Kettering)
Clifford A. Hudis, MD (Memorial Sloan-Kettering)
Gabriel N. Hortobagyi, MD (MD Anderson)

Non-Small Cell Chandra P. Belani, MD (University of Pittsburgh)
Lung Paul A. Bunn, Jr., MD (University of Colorado)
Mark G. Kris, MD (Memorial Sloan-Kettering)

Colorectal Leonard B. Saltz, MD (Memorial Sloan-Kettering)
Daniel G. Haller, MD (University of Pennsylvania)
Robert J. Mayer, MD (Dana-Farber/Harvard)

Prostate Daniel P. Petrylak, MD (Columbia University)
Mario A. Eisenberger, MD (Johns Hopkins University)
Howard I. Scher, MD (Memorial Sloan-Kettering)

Head and Neck Everett E. Vokes, MD (University of Chicago)
Arlene A. Forastiere, MD (Johns Hopkins University)
Marshall R. Posner, MD (Dana-Farber/Harvard)

Melanoma John M. Kirkwood, MD (University of Pittsburgh)
Steven A. Rosenberg, MD, PhD (National Cancer Instit.)
Donald L. Morton, MD (John Wayne Cancer Institute)

Non-Hodgkin's James O. Armitage, MD (University of Nebraska)
Lymphoma Sandra J. Horning, MD (Stanford University)
Julie M. Vose, MD (University of Nebraska)

Ovarian Robert F. Ozols, MD, PhD (Fox Chase)
J. Tate Thigpen, MD (University of Mississippi)
Maurie Markman, MD (MD Anderson)

Pancreatic James L. Abbruzzese, MD (MD Anderson)
Margaret A. Tempero, MD (University of California, SF)
Robert L. Fine, MD (Columbia University)

[Gold Seeker]

Do you understand now? Moro does not determine what is useful and what is not useful. He only develops tools and he in fact may be off in left field as to what the thought leaders want.

Moro is obviously wrong about the POC device when the very company that he intends to use to develop the POC state that testing is moving OUT of the doctors offices, Not INTO the doctors offices as Moro stated.